New imaging procedures in cancer surgery: Helmholtz High Impact Award for Oliver Bruns and Ellen Sletten

In optical imaging in humans, the greatest challenge is to penetrate the tissue. Current imaging techniques in medicine reach their limits in deeper tissue layers. In cancer treatment, for instance, residual tumors or individual cancer cells at the margins of tumors and in lymph nodes cannot yet be detected. Professor Ellen Sletten and Professor Oliver Bruns are now being given the Helmholtz High Impact Award 2024 for their newly developed method of combining short-wave infrared light with special fluorescent dyes and state-of-the-art camera technology to make these hitherto undetectable tumor cells visible.

“By using infrared in imaging, we can determine different tissue types based on their water content,” says Oliver Bruns when explaining the process known as SWIR imaging. In combination with special fluorescent dyes, we can now target certain tissues and structures, such as tumors or blood vessels, and make them visible. This is what the scientists are currently investigating. “The development of new contrast agents allows surgeons to detect tumors more precisely during surgery. Our contrast agents illuminate the edge of the tumor and make it easier to remove only the cancerous tissue while preserving as much healthy tissue as possible,” adds Ellen Sletten. 

The intention is to put the technology to use as quickly as possible. The National Center for Tumor Diseases Dresden (NCT/UCC) provides the ideal setting for Ellen Sletten and Oliver Bruns’ research. The joint institution involving the German Cancer Research Center (German abbreviation: DKFZ), the Faculty of Medicine at TU Dresden, the Carl Gustav Carus University Hospital Dresden and the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) has set itself the goal of improving cancer treatment for patients, using the latest technologies. “For the imaging systems, we are currently conducting clinical studies together with physicians in Dresden and Stanford to demonstrate benefits for patients,” says Bruns.  

Oliver Bruns has headed the Department of Functional Imaging in Surgical Oncology at NCT/UCC Dresden since 2022. He holds a DKFZ-funded Chair at the Faculty of Medicine of TU Dresden. Previously, he was employed at the Helmholtz Pioneer Campus Munich, where a large part of the research that is now being honored by this award was carried out. Ellen Sletten is a professor at the University of California, Los Angeles (UCLA) and is one of the most renowned chemists at her university. She is particularly well known for her research on short-wave infrared dyes.

Ellen Sletten and Oliver Bruns are delighted to have their years of research recognized: “We have been working together on this project for a decade. It is great to see how much we have already been able to achieve,” says Ellen Sletten. 

“The research of Professor Bruns and Professor Sletten will revolutionize imaging in surgery in the coming years,” Esther Troost, Dean of the Faculty of Medicine, firmly believes. “It is fantastic that Professor Bruns and his team, who have been working on this technology for years, will provide major benefits to research and clinical practice,” adds Professor Michael Albrecht, Medical Director at Dresden University Hospital.

Just recently, to further advance this highly innovative technology, Oliver Bruns and Ellen Sletten were awarded a 2.2 million US dollar grant from the Chan Zuckerberg Initiative for their outstanding research at the interface of biology, chemistry, engineering and medicine. 

Further information about the High Impact Award 2024: Youtube.

For more information on Professor Oliver Bruns’ research: Detecting minute cancer cells in the operating theater  

Contact:
National Center for Tumor Diseases Dresden (NCT/UCC)
Fetscherstraße 74/PF 64
01307 Dresden
Tel.: +49 351 458 3371
Email: info(at)nct-dresden.de
www.nct-dresden.de

Anne-Stephanie Vetter
Staff Unit Public Relations of Carl Gustav Carus Faculty of Medicine 
at TUD Dresden University of Technology
National Center for Tumor Diseases (NCT/UCC) Dresden
Tel.: +49 351 458 17903
Email: anne-stephanie.vetter(at)tu-dresden.de
www.tu-dresden.de/med

National Center for Tumor Diseases Dresden (NCT/UCC) 
The National Center for Tumor Diseases Dresden is a joint institution involving the German Cancer Research Center (German abbreviation: DKFZ), the Faculty of Medicine at TU Dresden, the Carl Gustav Carus University Hospital Dresden and the Helmholtz-Zentrum Dresden-Rossendorf (HZDR). The NCT Dresden is part of NCT, which has sites in Berlin, Heidelberg, SouthWest (Tübingen-Stuttgart/Ulm), WERA (Würzburg, Erlangen, Regensburg, Augsburg) and West (Essen/Cologne).
The NCT has made it its mission to link research and patient care as closely as possible. It is a long-term collaboration between the German Cancer Research Center (German abbreviation: DKFZ), excellent partners at the university medical center, and other outstanding research partners at various locations in Germany. The NCT aims at translating innovations in cancer research in Germany into studies in a targeted and rapid manner, with the aim of diagnosing and treating cancer while maintaining a high quality of life. In doing so, patients are research partners on an equal footing.
The Dresden center draws on the structures of the University Cancer Center Dresden (UCC), which was founded in 2003 as one of the first Comprehensive Cancer Centers (CCC) in Germany. Since 2007, the Dresden center has repeatedly been awarded the title of “Oncological Center of Excellence” by the German Cancer Aid (German abbreviation: DKH).